In this role John uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and mood disorders. John’s scientific interests centre on synaptic mechanisms in circuit function, and how dysfunction causes psychiatric and neurological disease. John now co-leads the DPUK’s Synaptic health working group. He works closely with colleagues at the University of Cambridge in the New Therapeutics in Alzheimer’s Disease (NTAD) study, which is looking to identify sensitive and tractable neurophysiological biomarkers for next generation experimental medicine studies.
John is speaking in the ‘How DPUK helped me’ session.